Literature DB >> 1581439

Anticholinergic drug effects on quantitative electroencephalogram, visual evoked potential, and verbal memory.

E P Sloan1, G W Fenton, K P Standage.   

Abstract

Electroencephalographic (EEG) power and coherence spectrum and visual evoked potential (VEP) recordings were made in a group of control subjects on two occasions, a week apart, before and after the subcutaneous administration of either 0.6 mg scopolamine (hyoscine-hydrobromide), a centrally acting anticholinergic drug, or 0.5 mg methscopolamine nitrate, a peripherally acting anticholinergic drug. After scopolamine administration, the EEG power spectrum significantly slowed and EEG coherence at the alpha and beta frequencies decreased. Left interhemispheric coherence increased at 1 Hz and 3-7 Hz. Methscopolamine had no significant effect on the quantitative EEG. The latency of the major positive components of the VEPs, to both flash and pattern stimuli, were not significantly affected by either drug. Verbal memory was significantly reduced after scopolamine. The results suggest that previous reports of scopolamine-induced changes in the EEG power spectrum and in verbal memory can be attributed to the central action of the drug rather than to peripheral side effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1581439     DOI: 10.1016/0006-3223(92)90246-v

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  15 in total

1.  Changes in electrocortical power and coherence in response to the selective cholinergic immunotoxin 192 IgG-saporin.

Authors:  D P Holschneider; J J Waite; A F Leuchter; N Y Walton; O U Scremin
Journal:  Exp Brain Res       Date:  1999-05       Impact factor: 1.972

Review 2.  Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings.

Authors:  Susanne Graef; Peter Schönknecht; Osama Sabri; Ulrich Hegerl
Journal:  Psychopharmacology (Berl)       Date:  2011-01-08       Impact factor: 4.530

3.  Cholinesterase inhibitors affect brain potentials in amnestic mild cognitive impairment.

Authors:  Rie Irimajiri; Henry J Michalewski; Edward J Golob; Arnold Starr
Journal:  Brain Res       Date:  2007-02-02       Impact factor: 3.252

4.  Tackling the Electro-Topography of the Selves Through the Sphere Model of Consciousness.

Authors:  Patrizio Paoletti; Rotem Leshem; Michele Pellegrino; Tal Dotan Ben-Soussan
Journal:  Front Psychol       Date:  2022-05-19

5.  Abnormal cortical functional connections in Alzheimer's disease: analysis of inter- and intra-hemispheric EEG coherence.

Authors:  Zheng-yan Jiang
Journal:  J Zhejiang Univ Sci B       Date:  2005-04       Impact factor: 3.066

6.  Abnormal phase discontinuity of alpha- and theta-frequency oscillations in schizophrenia.

Authors:  Daisuke Koshiyama; Makoto Miyakoshi; Kumiko Tanaka-Koshiyama; Yash B Joshi; Joyce Sprock; David L Braff; Gregory A Light
Journal:  Schizophr Res       Date:  2021-03-27       Impact factor: 4.939

7.  Scopolamine effects on functional brain connectivity: a pharmacological model of Alzheimer's disease.

Authors:  R Bajo; S Pusil; M E López; L Canuet; E Pereda; D Osipova; F Maestú; E Pekkonen
Journal:  Sci Rep       Date:  2015-07-01       Impact factor: 4.379

8.  The EEG as an index of neuromodulator balance in memory and mental illness.

Authors:  Costa Vakalopoulos
Journal:  Front Neurosci       Date:  2014-04-08       Impact factor: 4.677

9.  Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease.

Authors:  Meenakshi Dauwan; Jessica J van der Zande; Edwin van Dellen; Iris E C Sommer; Philip Scheltens; Afina W Lemstra; Cornelis J Stam
Journal:  Alzheimers Dement (Amst)       Date:  2016-08-19

10.  Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium.

Authors:  Christine Thomas; Ute Hestermann; Juergen Kopitz; Konstanze Plaschke; Peter Oster; Martin Driessen; Christoph Mundt; Matthias Weisbrod
Journal:  BMC Neurosci       Date:  2008-09-15       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.